2019 is shaping up to be a tipping point in the nascent market for NASH (non-alcoholic steatohepatitis) treatments, but the first Phase III trial results suggest that the development of safe and effective therapies will be challenging.

At the same time, there are various clinical, financial, and emotional trends that will impact how brands can best engage and support patients, providers, and payers.

Here we review a few of these trends, and customer questions and planning considerations brands should explore as a result.


Sources: 1. U.S. EHR and claims analysis, 2018 (DRG); 2. Epidemiology data, 2018 (DRG); 3. KOL interviews, NASH Disease Landscape & Forecast, 2018 (DRG); 4. Anonymized social conversations acquired via Brandwatch; 5. Digital patient study, Cybercitizen Health® U.S., 2018 (DRG)


Do you know the right questions to get closer to your customers?

These dynamics, as well as complex patient, provider, and payer relationships and influences, make NASH commercial planning challenging.

DRG experts can help you prioritize the right questions and data sources to get you closer to your NASH customers.


Fill out the form to get:

  • Full infographic with key questions and planning considerations


Biotech set for good start to 2021

View Now